癌症單株抗體相關的聯盟和授權合約 (2016～2024年)

Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2024

出版日期: 2024年05月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供癌症單株抗體相關近來 (2016～2024年) 的聯盟授權合約趨勢相關分析，彙整整體交易數量的轉變，及財務方面 (付款條件) 的傾向，由於主要企業 (全25公司) 的交易形成的動向，契約條件的傾向，各技術詳細內容趨勢等調查，近幾年主要的聯盟交易內容等詳細資訊，為您概述為以下內容。

簡介
癌症單株抗體相關交易的長期趨勢
癌症單株抗體相關最活躍的交易業者
癌症單株抗體相關的交易:各交易類型
癌症單株抗體相關的交易:各治療領域
癌症單株抗體相關的交易:各業界
癌症單株抗體相關的交易:交易條件
- 癌症單株抗體相關的交易:交易總額
- 癌症單株抗體相關的交易:預付款金
- 癌症單株抗體相關的交易:階段性付款
- 癌症單株抗體相關的交易:使用費率

第3章癌症單株抗體相關的主要交易

簡介
癌症單株抗體相關的主要的交易:以契約金額為準

第4章癌症單株抗體相關最活躍的交易企業

簡介
癌症單株抗體相關交易上最活躍的企業
癌症單株抗體相關交易上最活躍的企業:簡介

第5章癌症單株抗體相關的契約締結一覽

簡介
癌症單株抗體相關的契約締結一覽

第6章癌症單株抗體相關的交易:各技術種類

交易一覽
交易一覽:癌症單株抗體相關，各企業 (ABC順序)
交易一覽:癌症單株抗體相關，各交易類型
交易一覽:癌症單株抗體相關，各治療領域
交易的種類定義
關於Biopharma Research Ltd
目前聯盟
目前契約
Current Partnering出版的最近報告標題

簡介目錄

Product Code: CP22012

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 599 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse cancer monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry
Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading cancer monoclonal antibody deals by value
Most active cancer monoclonal antibody licensing dealmakers
Cancer Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody deals over the years
2.3. Most active cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody deals by deal type
2.5. Cancer monoclonal antibody deals by therapy area
2.6. Cancer monoclonal antibody deals by industry sector
2.7. Deal terms for cancer monoclonal antibody deals
- 2.7.1 Cancer monoclonal antibody deals headline values
- 2.7.2 Cancer monoclonal antibody deal upfront payments
- 2.7.3 Cancer monoclonal antibody deal milestone payments
- 2.7.4 Cancer monoclonal antibody royalty rates